Marc C. Chamberlain

27.6k citations

329 papers · 17.9k indexed · 4 hit papers · h-index 66

Impact in

Genetics top 0.01%
- Glioma Diagnosis and Treatment
Neurology top 0.1%
- CNS Lymphoma Diagnosis and Treatment
- Neurofibromatosis and Schwannoma Cases

Papers in

Genetics 210
- Glioma Diagnosis and Treatment 209
Neurology 86
- CNS Lymphoma Diagnosis and Treatment 42

Co-authors: Michael Glantz Patty A. Kormanik Patrick Y. Wen Martin J. van den Bent Sandra K. Johnston Ana M. Aparicio Michael A. Vogelbaum Wolfgang Wick
Journals: Journal of Neuro-Oncology (50 papers)Journal of Clinical Oncology (35 papers)Cancer (30 papers)Neuro-Oncology (25 papers)Expert Review of Neurotherapeutics (19 papers)
Partner nations: United States France South Africa

In The Last Decade

Marc C. Chamberlain

322 papers receiving 17.5k citations

Hit Papers

align trajectories log scale

Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas 2016 · 490 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2016 Neuro-Oncology
2014 Journal of neurosurgery
2011 The Lancet Oncology
2010 Journal of Clinical Oncology

Peers

Countries citing papers authored by Marc C. Chamberlain

Since Specialization

Citations

This map shows the geographic impact of Marc C. Chamberlain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc C. Chamberlain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc C. Chamberlain more than expected).

Fields of papers citing papers by Marc C. Chamberlain

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marc C. Chamberlain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc C. Chamberlain. The network helps show where Marc C. Chamberlain may publish in the future.

Co-authors

The 25 scholars most cited alongside Marc C. Chamberlain, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Marc C. Chamberlain Line = papers co-authored together Marc C. Chamberlain links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	PET imaging in patients with brain metastasis—report of the RANO/PET group Neuro-Oncology ·Norbert Galldiks, Karl‐Josef Langen, Nathalie L. Albert, Marc C. Chamberlain, Riccardo Soffietti, Michelle M. Kim, Ian Law, Émilie Le Rhun, Susan M. Chang, Julian Schwarting, Stephanie E. Combs, Matthias Preusser, Peter Forsyth, Whitney B. Pope, Michael Weller, Jörg C. Tonn	2019	122
2	Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group Neuro-Oncology ·Nils D. Arvold, Terri S. Armstrong, Katherine E. Warren, Susan M. Chang, Lisa M. DeAngelis, Jaishri O. Blakeley, Marc C. Chamberlain, Erin Dunbar, Herbert H. Loong, David R. Macdonald, David A. Reardon, Michael A. Vogelbaum, Ying Yuan, Michael Weller, Martin J. van den Bent, Patrick Y. Wen	2018	37
3	Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study The Lancet Oncology ·Rashmi K. Murthy, Virginia F. Borges, Alison Conlin, Jorge Chaves, Marc C. Chamberlain, Todd Gray, Alex Vo, Erika Hamilton	2018	129
4	Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy Neuro-Oncology ·Patrick Y. Wen, Jan Drappatz, John de Groot, Michael D. Prados, David A. Reardon, David Schiff, Marc C. Chamberlain, Tom Mikkelsen, Annick Desjardins, Jaymes Holland, Jerry Ping, Ron Weitzman, Timothy F. Cloughesy	2017	85
5	Treatment of primary CNS lymphoma (PCNSL) following successful treatment of systemic non-Hodgkin’s lymphoma (NHL): a case series Journal of Neuro-Oncology ·Marc C. Chamberlain	2013	4
6	A novel treatment for glioblastoma: integrin inhibition Expert Review of Neurotherapeutics ·Marc C. Chamberlain, Timothy Cloughsey, David A. Reardon, Patrick Y. Wen	2012	29
7	Repair of 3-methyladenine and abasic sites by base excision repair mediates glioblastoma resistance to temozolomide SHILAP Revista de lepidopterología ·Michael S. Bobola, Douglas D. Kolstoe, A. Blank, Marc C. Chamberlain, John R. Silber	2012	42
8	Neuro-oncology: a selected review of ASCO 2011 abstracts Expert Review of Neurotherapeutics ·Marc C. Chamberlain	2011	1
9	Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma Journal of Clinical Oncology ·Wolfgang Wick, Vinay K. Puduvalli, Marc C. Chamberlain, Martin J. van den Bent, Alain Carpentier, Lawrence Cher, Warren Mason, Michael Weller, Shengyan Hong, Luna Musib, Astra M. Liepa, Donald Thornton, Howard A. Fine	2010	359
10	Hodgkin's Lymphoma: A Review of Neurologic Complications Advances in Hematology ·Sean Grimm, Marc C. Chamberlain	2010	44
11	High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma Neuro-Oncology ·Marc C. Chamberlain, Sandra K. Johnston	2010	70
12	Talampanel With Standard Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma: A Multicenter Phase II Trial Journal of Clinical Oncology ·Stuart A. Grossman, Xiaobu Ye, Marc C. Chamberlain, Tom Mikkelsen, Tracy T. Batchelor, Serena Desideri, Steven Piantadosi, Joy Fisher, Howard A. Fine	2009	131
13	Salvage therapy with single agent bevacizumab for recurrent glioblastoma Journal of Neuro-Oncology ·Marc C. Chamberlain, Sandra K. Johnston	2009	105
14	Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report Annals of Oncology ·Sean Grimm, José S. Pulido, Kristoph Jahnke, David Schiff, Anthony Hall, Tamara Shenkier, T. Siegal, Nancy D. Doolittle, Tracy T. Batchelor, Ulrich Herrlinger, Edward A. Neuwelt, Normand Laperrière, Marc C. Chamberlain, Jean‐Yves Blay, Andrés J.M. Ferreri, Antonio Omuro, E. Thiel, Lauren E. Abrey	2007	188
15	Intracerebral meningiomas Current Treatment Options in Neurology ·Marc C. Chamberlain	2004	24
16	Pharmacokinetics of Intralumbar DTC-101 for the Treatment of Leptomeningeal Metastases Archives of Neurology ·Marc C. Chamberlain, Patty A. Kormanik, Stephen B. Howell, S Kim	1995	68
17	Recurrent brainstem gliomas treated with oral VP-16 Journal of Neuro-Oncology ·Marc C. Chamberlain	1993	60
18	Osseous metastasis in medulloblastoma: MRI findings in an unusual case Clinical Imaging ·E M Olson, R D Tien, Marc C. Chamberlain	1991	9
19	Epidural spinal cord compression: Treatment options Seminars in Spine Surgery ·Marc C. Chamberlain, J. Abitbol, Steven R. Garfin	1990	3
20	Adjuvant Chemotherapy for Primary Lymphoma of the Central Nervous System Archives of Neurology ·Marc C. Chamberlain, Victor A. Levin	1990	39

About Marc C. Chamberlain

Marc C. Chamberlain is a scholar working on Genetics, Neurology, Pulmonary and Respiratory Medicine, Oncology and Epidemiology, having authored 329 papers that have together received 17.9k indexed citations. Recurring topics across this work include Glioma Diagnosis and Treatment (209 papers), Brain Metastases and Treatment (177 papers), Meningioma and schwannoma management (65 papers), Lung Cancer Research Studies (43 papers), CNS Lymphoma Diagnosis and Treatment (42 papers), Management of metastatic bone disease (39 papers), Head and Neck Surgical Oncology (32 papers) and Cancer Treatment and Pharmacology (22 papers). The work is most often cited by research in Genetics (10.9k citations), Neurology (4.2k citations), Pulmonary and Respiratory Medicine (7.4k citations), Oncology (4.1k citations) and Radiology, Nuclear Medicine and Imaging (3.0k citations). Marc C. Chamberlain has collaborated with scholars based in United States, France and South Africa. Frequent co-authors include Michael Glantz, Patty A. Kormanik, Patrick Y. Wen, Martin J. van den Bent, Sandra K. Johnston, Ana M. Aparicio, Michael A. Vogelbaum, Wolfgang Wick, David A. Reardon and Timothy F. Cloughesy. Their work appears in journals such as Journal of Neuro-Oncology, Journal of Clinical Oncology, Cancer, Neuro-Oncology and Expert Review of Neurotherapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact